治療に反応した後に再発した多発性骨髄腫患者、または治療に反応しなかった患者を対象に、治験薬（エルラナタマブ）について知るための研究

基本情報

NCT ID

NCT05014412

ステータス

実施中（募集終了）

試験のフェーズ

第2相

試験タイプ

介入

目標被験者数

86

治験依頼者名

Pfizer

概要

The purpose of the study (Part 1 and Part 2) is to evaluate the safety of a step-up dosing approach (starting with low doses followed by higher doses) of the study medicine (elranatamab) in participants with multiple myeloma that has come back after responding to treatment or has not responded to treatment (relapsed/refractory multiple myeloma). This study will also look at the safety and efficacy of different doses of elranatamab, as well as different intervals between doses. Participants in the study will receive elranatamab as an injection under the skin at the study clinic. After the initial step-up doses, participants will start receiving one dose every week. The frequency of clinic visits for injections may then decrease over time. Participation will be at least two years.

対象疾患

介入

依頼者（Sponsor）

実施施設 (5)